natgillin/translations-raw huggingface dataset:
Nivestim 30 ME/ 0,5 ml injektions-/infusionsvæske, opløsning Filgrastim
Nivestim 30 MU 0.5 ml solution for injection/infusion Filgrastim
Nivestim 30 ME/ 0,5 ml injektions-/infusionsvæske, opløsning, Nivestim 48 ME/ 0,5 ml injektions-
Nivestim 30 MU/ 0.5 ml solution for injection/infusion, Nivestim 48 MU/ 0.5 ml solution for injection/infusion
Nivestim 30 ME/ 0,5 ml injektions-/infusionsvæske, opløsning.
Nivestim 30 MU/ 0.5 ml solution for injection/infusion
Nivestim 48 ME/ 0,5 ml injektions-/infusionsvæske, hver fyldt sprøjte indeholder 48 millioner enheder (ME), 480 mikrogram filgrastim i 0,5 ml (det svarer til 0,96 mg/ml).
Nivestim 48 MU/ 0.5 ml solution for injection/ infusion: each pre-filled syringe contains 48 million units (MU), 480 micrograms of filgrastim in 0.5 ml (corresponding to 0.96 mg/ml).
Nivestim 48 ME/ 0,5 ml injektions-/infusionsvæske, opløsning Filgrastim
Nivestim 48 MU/0.5 ml solution for injection/infusion Filgrastim
Nivestim 48 ME/ 0,5 ml injektions-/infusionsvæske, opløsning.
Nivestim 48 MU/ 0.5 ml solution for injection/infusion
Nivestim anvendes til at stimulere dannelsen af hvide blodlegemer i følgende situationer:
Nivestim is used to stimulate the production of white blood cells in the following situations:
Nivestim blev sammenlignet med Neupogen i en hovedundersøgelse, som omfattede 279 kvinder med brystkræft, der blev behandlet med lægemidler mod kræft.
Nivestim was compared with Neupogen in one main study involving 279 women with breast cancer who were being treated with anticancer medicines.
Nivestim blev undersøgt for at påvise, at det er sammenligneligt med referencelægemidlet Neupogen.
Nivestim was studied to show that it is comparable to the reference medicine, Neupogen.
Nivestim bør aldrig fortyndes til en koncentration under 0,2 ME (2 mikrogram) pr. ml.
Dilution to a final concentration less than 0.2 MU (2 micrograms) per ml is not recommended at any time.
Nivestim bør ikke anvendes hos patienter, der kan være overfølsomme (allergiske) over for filgrastim eller andre af indholdsstofferne.
Nivestim should not be used in people who may be hypersensitive (allergic) to filgrastim or any of the other ingredients.
Nivestim bør ikke fortyndes til en slutkoncentration under 0,2 mio E (2 mikrogram) pr. ml.
Dilution to a final concentration less than 0.2 MU (2 micrograms) per ml is not recommended at any time.
Nivestim bør ikke påvirke din evne til at føre motorkøretøj eller betjene maskiner.
Nivestim should not affect your ability to drive and use machines.
Nivestim er en klar farveløs injektions-/infusionsvæske i en fyldt sprøjte af glas med kanyle (rustfrit stål) med en kanylebeskytter.
Nivestim is a clear colourless solution for injection/ infusion in a glass pre-filled syringe with an injection needle (stainless steel) with a needle guard.
Nivestim er en opløsning til injektion (drop i en vene), der indeholder det aktive stof filgrastim.
Nivestim is a solution for injection or infusion (drip into a vein) that contains the active substance filgrastim.
Nivestim er en vækstfaktor (granulocyt-kolonistimulerende faktor) for hvide blodlegemer og tilhører en gruppe af lægemidler, som kaldes cytokiner.
Nivestim is a white blood cell growth factor (granulocyte colony stimulating factor) and belong to a group of medicines called cytokines.
Nivestim er et lægemiddel i en gruppe af produkter, der stimulerer produktionen af de hvide blod- legemer.
Nivestim is one of a group of products that stimulate the production of white blood cells.
Nivestim er et »biosimilært« lægemiddel.
Nivestim is a ‘biosimilar’ medicine.
Nivestim gives normalt som en daglig indsprøjtning i vævet under huden (kaldes en subkutan injektion).
Nivestim is usually given as a daily injection into the tissue under the skin (known as a subcutaneous injection).
Nivestim gives sædvanligvis på et specialiseret behandlingscenter, selvom de patienter, der får lægemidlet gennem injektion under huden, selv kan give injektionerne, når de først er blevet behørigt instrueret heri.
Nivestim is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately.
Nivestim gives ved injektion under huden eller ved infusion i en vene.
Nivestim is given by injection under the skin or infusion into a vein.
Nivestim indeholder ikke konserveringsmiddel.
Nivestim contains no preservative.
Nivestim indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, d.v.s. det er praktisk taget natriumfri.
Nivestim contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially sodium-free.
Nivestim indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, dvs. praktisk taget natriumfrit.
Nivestim contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially sodium-free.
Nivestim indeholder natrium og sorbitol
Nivestim contains sodium and sorbitol
Nivestim kan bruges:
Nivestim can be used:
Nivestim kan om nødvendigt fortyndes med 50 mg/ml (5 %) glucoseinfusionsvæske.
If required, Nivestim may be diluted in 50 mg/ml (5%) glucose solution for infusion.
Nivestim kan om nødvendigt fortyndes med en 5 % glucoseinjektionsvæske (50 mg/ml), opløsning.
If required, Nivestim may be diluted in glucose 50 mg/ml (5%) solution for infusion.
Nivestim må ikke blandes med andre lægemidler end dem, som er nævnt nedenfor.
This medicinal product must not be mixed with other medicinal products except those mentioned below.
Nivestim må ikke fortyndes med natriumchlorid-opløsninger.
Nivestim must not be diluted with sodium chloride solutions.
Nivestim skal ikke fortyndes med natriumchloridopløsninger.
Nivestim must not be diluted with sodium chloride solution.
Nivestim, som indeholder r-metHuG-CSF (filgrastim), øger neutrofiltallet i perifert blod kraftigt indenfor 24 timer, med en mindre øgning af antallet af monocytter.
Nivestim containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within twenty-four hours, with minor increases in monocytes.
Nivestims holdbarhed påvirkes ikke, hvis det ved et uheld udsættes for nedfrysningstemperaturer i op til 24 timer.
Accidental exposure to freezing temperatures for up to 24 hours does not affect the stability of Nivestim.
Nivestims sikkerhed og virkning er vurderet i randomiserede, kontrollerede fase III-studier af brystcancer.
The efficacy and safety of Nivestim has been assessed in randomised, controlled phase III study in breast cancer.
Nivolumab 3 mg/kg
Number of Subjects at Risk Nivolumab 3 mg/kg
Nivolumab 3 mg/kg (hændelser: 183/410), median OS og 95% CI: 25,00 (21,75, N.A.)
Nivolumab 3 mg/kg (events: 183/410), median and 95% CI: 25.00 (21.75, N.A.)
Nivolumab 3 mg/kg viste en overordnet responsrate på 14,5% (95% CI: 8,7-22,2%), en median OS på 8,21 måneder (95% CI: 6,05-
Nivolumab 3 mg/kg showed an overall response rate of 14.5% (95% CI: 8.7-22.2%), a median OS of 8.21 months (95% CI: 6.05-10.9 months ), and a median PFS of
Nivolumab BMS 10 mg/ml koncentrat til infusionsvæske, opløsning.
Nivolumab BMS 10 mg/mL concentrate for solution for infusion.
Nivolumab BMS bør fortsættes under hormonsubstitutionsbehandlinga så længe, der ikke er symptomer
Nivolumab BMS should be continued in the presence of hormone replacement therapya as long as no symptoms are present
Nivolumab BMS kan gives som intravenøs administration enten:
Nivolumab BMS can be used for intravenous administration either:
Nivolumab BMS koncentrat til infusion, opløsning (sterilt koncentrat) er en klar til opaliserende, farveløs til lysegul væske, der kan indeholde få lyse partikler.
Nivolumab BMS concentrate for solution for infusion (sterile concentrate) is a clear to opalescent, colourless to pale yellow liquid that may contain few light particles.
Nivolumab BMS må ikke anvendes til børn og unge under 18 år.
Nivolumab BMS should not be used in children and adolescents below 18 years of age.
Nivolumab BMS må ikke infunderes samtidigt med andre lægemidler i samme infusionsslange.
Nivolumab BMS infusion should not be infused at the same time in the same intravenous line with other agents.
Nivolumab BMS må ikke infunderes samtidigt med andre lægemidler i samme infusionsslange.
Nivolumab BMS should not be infused concomitantly in the same intravenous line with other medicinal products.
Nivolumab BMS udleveres kun efter recept, og behandlingen skal påbegyndes og overvåges af en læge med erfaring i kræftbehandling.
Nivolumab BMS can only be obtained with a prescription and treatment must be started and supervised by a doctor experienced in the treatment of cancer.
Nivolumab BMS-infusion
Nivolumab BMS infusion
Nivolumab BMS-infusionsvæske er kompatibel med:
Nivolumab BMS infusion is compatible with:
Nivolumab BMS-koncentrat er en klar til opaliserende, farveløs til lysegul væske, der kan indeholde få lyse partikler.
Nivolumab BMS concentrate is a clear to opalescent, colourless to pale yellow liquid that may contain few light particles.
Nivolumab BMS-koncentrat kan fortyndes med enten: natriumchlorid 9 mg/ml (0,9%) injektionsvæske; eller
Nivolumab BMS concentrate may be diluted with either: sodium chloride 9 mg/mL (0.9%) solution for injection; or
Nivolumab BMS’ sikkerhed og virkning hos børn under 18 år er ikke klarlagt.
The safety and efficacy of Nivolumab BMS in children below 18 years of age have not been established.
Nivolumab er opbygget, så det binder sig til en receptor kaldet PD-1, som findes i visse af immunsystemets celler, som kaldes T-celler.
Nivolumab has been designed to attach to a receptor called PD-1 which is found on certain cells of the immune system called T cells.
Nivolumab i kombination med ipilimumab
Nivolumab in combination with ipilimumab
Nivolumab i kombination med ipilimumab bør seponeres ved livstruende eller tilbagevendende alvorlige kardielle og pulmonale bivirkninger.
Nivolumab in combination with ipilimumab should be discontinued for life-threatening or recurrent severe cardiac and pulmonary adverse reactions.
Nivolumab kobler sig til et målprotein kaldet programmeret celledød-1 (PD-1), som kan slukke for aktiviteten af T-cellerne (en type hvide blodlegemer, der udgør en del af immunsystemet, kroppens naturlige forsvarssystem).
Nivolumab attaches to a target protein called programmed death-1 receptor (PD-1) that can switch off the activity of T cells (a type of white blood cell that forms part of the immune system, the body’s natural defences).
Nivolumab og nivolumab i kombination med ipilimumab er associeret med immunrelaterede bivirkninger.
Nivolumab or nivolumab in combination with ipilimumab is associated with immune-related adverse reactions.
Nivolumab skal seponeres permanent i tilfælde af enhver recidiverende alvorlig immunrelateret bivirkning og enhver livstruende immunrelateret bivirkning.
Nivolumab must be permanently discontinued for any severe immune related adverse reaction that recurs and for any life threatening immune related adverse reaction.
Nivolumab versus ipilimumab (primær analyse) - HR (99,5% CI): 0,55 (0,42; 0,73); p-værdi: <0,0001
Nivolumab vs ipilimumab (primary analysis) - HR (99.5% CI): 0.55 (0.42, 0.73); p-value: <0.0001
Nivolumab+ipilimumab versus nivolumab (deskriptiv analyse) - HR (95% CI): 0,76 (0,62; 0,95)
Nivolumab+ipilimumab vs nivolumab (descriptive analysis) - HR (95% CI): 0.76 (0.62, 0.95)
Nivolumab-monoterapi
Nivolumab monotherapy
Niños y adolescentes
Children and adolescents
Niños y adolescentes (2 a 18 años)
Children and adolescents (2-18 years old)
NK- (naturlige dræberceller)-celletal og T-celletal
Natural killer (NK) cell and T-cell count
NK-celler vides at udtrykke høje niveauer af CD38 og er følsomme for daratumumab-medieret cellelyse.
NK cells are known to express high levels of CD38 and are susceptible to daratumumab mediated cell lysis.
NL - 1077 ZX Amsterdam Holland
NL - 1077 ZX Amsterdam The Netherlands
NL - 1077 ZX Amsterdam, Holland
NL - 1077 ZX Amsterdam, The Netherlands
NL- 1077 ZX Amsterdam Holland
NL - 1077 ZX Amsterdam The Netherlands
NL-1411 DD Naarden Holland
NL-1411 DD Naarden The Netherlands
NL-1411DD Naarden Holland
NL-1411DD Naarden The Netherlands
NL-2031 Haarlem Holland
NL-2031 Haarlem The Netherlands
NL-2333 CB Leiden Holland
2333 CB Leiden The Netherlands
NL-2333 CN Leiden Holland
NL-2333 CN Leiden Netherlands
NL-2333 CR Leiden Holland
NL-2333 CR Leiden The Netherlands
NL-4941 SJ Raamsdonksveer Nederlandene
NL-4941 SJ Raamsdonksveer The Netherlands
NL-5612 AZ, Eindhoven Holland
NL-5612 AZ, Eindhoven The Netherlands
NL-5612 AZ, Eindhoven Nederlandene
NL-5612 AZ, Eindhoven The Netherlands
NL-6229 EV, Maastricht Holland
NL-6229 EV, Maastricht The Netherlands
NMS er en potentielt livstruende tilstand, som er forbundet med antipsykota.
NMS is a potentially life-threatening condition associated with antipsychotic medicinal products.
NMS er en potentielt livstruende tilstand, som er forbundet med antipsykotik.
NMS is a potentially life-threatening condition associated with antipsychotic medicinal products.
NMS er en potentielt livstruende tilstand, som er forbundet med antipsykotika.
NMS is a potentially life-threatening condition associated with antipsychotic medicinal product.
NMS er en potentielt livstruende tilstand, som er forbundet med antipsykotikisk behandling.
NMS is a potentially life-threatening condition associated with antipsychotic medicinal products.
NMS er en potentielt livstruende tilstand, som er forbundet med antipsykotisk behandling.
NMS is a potentially life-threatening condition associated with antipsychotic medicinal product.
NMS er en potentielt livstruende tilstand, som er forbundet med antipsykotka.
NMS is a potentially life-threatening condition associated with antipsychotic medicinal products.
NMS er et potentielt dødeligt symptomkompleks, der er forbundet med antipsykotika.
NMS is a potentially fatal symptom complex associated with antipsychotic medicinal products.
NMS er et potentielt letalt symptomkompleks forbundet med antipsykotiske lægemidler.
NMS is a potentially fatal symptom complex associated with antipsychotic medicinal products.
NN:
159
NN:
Linearity
NN:˃
NN:>
NNRTI + PROTEASEHÆMMERE
NNRTI + PI
NNRTI 78%
NNRTI 78
NNRTI'ere
NNRTIs
NNRTI-baseret
NNRTI-based
NNRTI-koncentrationerne kan falde (isavuconazols CYP2B6- induktion) eller stige.
NNRTI concentrations may decrease (CYP2B6 induction by isavuconazole) or increase.
NNRTI-midler
NNRTIs
NNRTIer/efavirenz
Maraviroc:
NNRTI’er
NNRTIs
NNRTI’ere
NNRTIs
NNRTI‟er, nonnukleoside reverse transkriptasehæmmere; P-gp, P-glycoprotein.
NNRTI, non-nucleoside reverse-transcriptase inhibitor; P-gp, P-glycoprotein.
NNT for den samlede pædiatriske population var 9 (95 % konfidensinterval 7-24) og 8 (95 % konfidensinterval 6, øvre grænse kan ikke estimeres) i henholdsvis den samlede population (ITT) og i pædiatriske kontakter af inficerede indekstilfælde (ITTII).
The NNT for the total paediatric population was 9 (95 % CI 7 – 24) and 8 (95 % CI 6, upper limit not estimable) in the whole population (ITT) and in paediatric contacts of infected index cases (ITTII), respectively.
NNT for den samlede pædiatriske population var 9 (95 % konfidensinterval 7-24) og 8 (95 % konfidensinterval 6, øvre grænse kan ikke estimers) i henholdsvis den samlede population (ITT) og i pædiatriske kontakter af inficerede indekstilfælde (ITTII).
The NNT for the total paediatric population was 9 (95 % CI 7 – 24) and 8 (95 % CI 6, upper limit not estimable) in the whole population (ITT) and in paediatric contacts of infected index cases (ITTII), respectively.
NNT i dette studie var 25 (95 % konfidensinterval: 23-62).
The NNT in this study was 25 (95 % CI 23 – 62).
NNT i dette studie var 28 (95 % konfidensinterval: 24-50).
The NNT in this study was 28 (95 % CI 24 – 50).
No carrier added (n.c.a.) lutetium (177Lu)-chlorid (uden bærerstof) fremstilles ved bestråling af højt beriget (> 99 %) ytterbium (176Yb) i neutronkilder med en termisk neutronflux mellem 1.013 og 1.016 per cm2 per s (cm-2s-1).
Non carrier added (n.c.a.) Lutetium (177Lu) chloride is produced by the irradiation of highly enriched (> 99 %) Ytterbium (176Yb) in neutron sources with a thermal neutron flux between 1013 and 1016 cm- 2s-1.
No conduzca ni maneje herramientas o máquinas si se marea durante el tratamiento con Siklos.
Do not drive or use any tools or machines if you experience dizziness whilst taking Siklos.
No conservar a temperatura superior a 30°C.
Store below 30C.
No debe amamantar al niño mientras usa Siklos.
You must not breast-feed while taking Siklos.
No hay datos concretos que respalden ajustes de la dosis en pacientes con insuficiencia hepática.
There are no data that support specific dose adjustments in patients with hepatic impairment.
No hay datos que permitan proponer instrucciones concretas para ajustar la dosis en pacientes con insuficiencia hepática pero, por seguridad, Siklos está contraindicado en pacientes con insuficiencia hepática grave (ver sección 4.3).
There are no data that support specific guidance for dose adjustment in patients with hepatic impairment, but, due to safety considerations, Siklos is contraindicated in patients with severe hepatic impairment (see section 4.3).
No interrumpa el tratamiento a menos que se lo indique su médico.
Do not stop your treatment unless advised by your doctor.
No Observed Effect Level (NOEL) for unge rotter anses for at være 6 mg/kg/dag baseret på en reduktion i kropsvægt hos begge køn og en forsinket preputial seperation hos hanrotter (som kan skyldes vægtreduktionen).
Based on a reduction in body weight in both genders and a delayed preputial separation in males (which may be associated with the reduction in weight), the No-Observed-Effect- Level in juvenile rats was considered to be 6 mg/kg/day.
No obstante, se informará a los pacientes de que en la bibliografía aparecen casos de mareos, aunque no son frecuentes.
However, patients should be informed that dizziness has been reported from literature, but not commonly.
No obstante, se supone que es carcinógena para varias especies.
However, hydroxycarbamide is presumed to be a transspecies carcinogen.
No procede.
Not applicable.
No se conoce completamente el mecanismo de acción concreto de la hidroxicarbamida.
The specific mechanism of action of hydroxycarbamide is not fully understood.
No se conocen bien las vías de biotransformación ni los metabolitos.
The biotransformation pathways as well as the metabolites are not fully characterised.
No se dispone de datos en pacientes con insuficiencia hepática de leve a moderada, por lo que Siklos debe utilizarse con precaución.
Since there is no available data in patients with mild to moderate liver impairment, Siklos should be used with caution.
No se dispone de datos en pacientes con insuficiencia hepática entre leve y moderada, por lo que Siklos debe utilizarse con precaución.
Since there is no available data in patients with mild to moderate liver impairment, Siklos should be used with caution.
No se han realizado estudios convencionales a largo plazo sobre el poder carcinógeno de hidroxicarbamida.
Conventional long-term studies to evaluate the carcinogenic potential of hydroxycarbamide have not been performed.
No se han realizado estudios de interacciones específicos con hidroxicarbamida.
Specific interaction studies have not been performed with hydroxycarbamide.
No se han realizado estudios de los efectos sobre la capacidad para conducir y utilizar máquinas.
No studies on the effect on the ability to drive and use machines have been performed.
No se recomienda tomar Siklos durante el embarazo.
Siklos is not recommended during pregnancy.
No utilice Siklos después de la fecha de caducidad que aparece en la caja y el frasco después de CAD.
Do not use Siklos after the expiry date which is stated on the carton and the bottle after EXP.
NO, NO2 og O2-monitorkalibrering
NO, NO2 and O2 monitor calibration
NO-1325 Lysaker Tlf: +47 24 12 65 00
NO-1325-Lysaker Tlf: +47 24 12 65 00
NO-1325-Lysaker Tlf: +47 24 12 65 00
NO-1325-Lysaker Tlf: + 47 24 12 65 00
NO16966: Avastin 7,5 mg/kg legemsvægt hver 3. uge i kombination med oral capecitabin og intravenøs oxaliplatin (XELOX) eller Avastin 5 mg/kg hver 2. uge i kombination med leucovorin plus 5-fluoruracil bolus efterfulgt af 5-fluoruracil infusion og intravenøs oxaliplatin (FOLFOX-4).
NO16966: Avastin 7.5 mg/kg of body weight every 3 weeks in combination with oral capecitabine and intravenous oxaliplatin (XELOX) or Avastin 5 mg/kg every 2 weeks in combination with leucovorin plus 5-fluorouracil bolus, followed by 5-fluorouracil infusion, with intravenous oxaliplatin (FOLFOX-4).
NOAEL (no observed adverse effect level) for embryoføtal toksicitet i dette studie var 10 mikrogram/kg/dag, hvilket svarede til en systemisk eksponering på cirka 3-5 gange de eksponeringer, der observeres hos patienter, som behandles med den kliniske dosis.
The no observed adverse effect level for embryo-fetal toxicity in this study was 10 micrograms/kg/day, which corresponded to a systemic exposure of approximately 3-5 times the exposures observed in patients treated with the clinical dose.
NOAEL (No Observed Adverse Effect Level) var 3.600 mg/kg/dag for gravide hunrotter (12 x MRHD (Maximum Recommended Human Dose) på basis af mg/m2) og 1.200 mg/kg/dag for fostre.
The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2 basis) and 1200 mg/kg/day for foetuses.
NOAEL for embryo-føtal toksicitet og teratogene fund var lavere end det humane kliniske eksponeringsniveau ved den tilsigtede terapeutiske dosis.
NOAEL for embryo-foetal toxicity and teratogenic findings were below human clinical exposure levels at intended therapeutic dose.
NOAEL for toksicitet i moderdyret, embryo- føtal toksicitet og toksicitet i afkommet hos rotter var 49 gange den humane eksponering.
The NOAEL for maternal-, embryo-fetal-, and offspring toxicity in rats was 49 times human exposure.
NOAEL var ≥ 1.800 mg/kg/dag for F0-hunnerne samt for overlevelse, vækst og udvikling af F1-afkom indtil ophør af diegivning (6 x MRHD på basis af mg/m2).
The NOAEL was ≥ 1800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning.(x 6 the MRHD on a mg/m2 basis).
NOAEL var ≥1.800 mg/kg/dag for F0-hunnerne samt for overlevelse, vækst og udvikling af F1-afkom indtil ophør af diegivning (6 x MRHD på basis af mg/m2).
The NOAEL was ≥ 1800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning.(x 6 the MRHD on a mg/m2 basis).
NOAL-værdien (no observed adverse effect) for påvirkningen af reproduktionsevnen hos hunrotter (100 mg/kg/dag) var omkring 16 gange den anbefalede maksimumdosis for mennesker, baseret på mg/m2.
The no observed adverse effect level (NOAEL) for effects on reproduction in females (100 mg/kg/day) was about 16-times the maximum human recommended dose on a mg/m2 basis.
Nobilis IB 4-91 er udelukkende beregnet til beskyttelse af kyllinger mod respiratoriske symptomer på sygdom, der er forårsaget af IBV-stammevariant 4-91, og bør ikke anvendes som erstatning for andre IBV vacciner.
Nobilis IB 4-91 is intended to protect chickens against respiratory signs of disease caused by IBV variant strain 4-91 only and should not be used as a replacement for other IBV vaccines.
Nobilis IB 4-91 lyofilisat, suspension til kyllinger
Nobilis IB4-91, lyophilisate for suspension for chicken
Nobilis IB 4-91, lyofilisat til suspension til kyllinger
Nobilis IB 4-91, lyophilisate for suspension for chicken
Nobilis IB 4-91, lyofilisat, suspension til kyllinger
Nobilis IB 4-91, lyophilisate for suspension for chicken
Nobilis IB Primo QX, lyofilisat og solvens til suspension, til kyllinger Nobilis IB Primo QX, lyofilisat til suspension, til kyllinger
Nobilis IB Primo QX lyophilisate and solvent for suspension for chicken Nobilis IB Primo QX lyophilisate for suspension for chicken
Nobilis IB Primo QX, lyofilisat og solvens til suspension, til kyllinger Nobilis IB Primo QX, lyofilisat til suspension, til kyllinger
Nobilis IB Primo QX lyophilisate and solvent for suspension for chickens Nobilis IB Primo QX lyophilisate for suspension for chickens
Nobilis IB Primo QX, lyofilisat til suspension, til kyllinger
Nobilis IB Primo QX lyophilisate for suspension for chicken